TIDMFUM
RNS Number : 6427A
Futura Medical PLC
03 June 2021
3 June 2021
Futura Medical plc
("Futura" or the "Company")
Notice of AGM and Annual Report
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology and currently focused on sexual health and
pain, announces its Annual General Meeting ("AGM") will be held at
10:00 am on Monday 28 June 2021 at the offices of Liberum,
Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.
The Board has been closely monitoring the evolving Coronavirus
(COVID-19) situation and recognises that UK Government guidance
continues to require social distancing and prohibition of mass
gatherings.
Only the minimum number of directors who are shareholders will
attend in person to ensure a quorum is present. Accordingly, so as
to ensure their vote is counted at the AGM, all shareholders are
asked to submit a Form of Proxy, instructing the Chairman of the
Meeting on how they wish to vote on the proposed resolutions.
Shareholder engagement
The Board recognises the ongoing importance of communication
with shareholders at this time. The Company will operate an audio
dial-in facility to allow shareholders to listen to the business of
the meeting: Shareholders will need to be confirmed as a
shareholder or present a letter of representation before details of
how to access this facility are released to them via email on the
morning of the meeting. You can request access by emailing:
investor.relations@futuramedical.com prior to 10:00 am on 24 June
2021.
Shareholders who wish to attend the AGM in person against our
recommendation will need to pre-register their intention to do so
by email using investor.relations@futuramedical.com by no later
than 10:00 am on 24 June 2021 to ensure access to the venue.
Reminder to vote by proxy
You will not receive a hard copy form of proxy for the 2021 AGM
in the post. Instead, you will be able to vote electronically using
the link www.signalshares.com. You will need to log into your
Signal Shares account, or register if you have not previously done
so, to register you will need your Investor Code, this is detailed
on your share certificate or available from our Registrar, Link
Group. You may request a hard copy form of proxy directly from the
registrars, Link Group, on Tel: 0371 664 0391. Proxy votes must be
received no later than 10:00 am on 24 June 2021.
Further updates
The Board will continue to monitor the situation and may, if
necessary, need to make further changes to the arrangements for the
AGM, including how it is conducted. Shareholders should therefore
continue to monitor the Company's website and announcements.
The Board would like to thank shareholders for their
understanding and support during these exceptional circumstances
and wish them well during these challenging times.
Annual Report
Futura's annual report and accounts for the year ended 31
December 2020 (the "Annual Report") is available to shareholders as
an electronic communication pursuant to the Companies Act 2006 and
is now available at the Company's website www.futuramedical.com ,
along with the Notice of AGM.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 20 3922 0900
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAEAKKAEDPFEFA
(END) Dow Jones Newswires
June 03, 2021 06:00 ET (10:00 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024